학술논문
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Document Type
Article
Author
Source
In The Lancet Oncology January 2020 21(1):44-59
Subject
Language
ISSN
1470-2045